Delayed low-dose oral administration of 4'-fluorouridine inhibits pathogenic arenaviruses in animal models of lethal disease.
СтатьяПоддержка NIH: внешняя программаResearch Support, N.I.H., IntramuralПоддержка правительства СШАПоддержка службы здравоохранения СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Welch Stephen R, Spengler Jessica R, Westover Jonna B, Bailey Kevin W, Davies Katherine A, Aida-Ficken Virginia, Bluemling Gregory R, Boardman Kirsten M, Wasson Samantha R, Mao Shuli, Kuiper Damien L, Hager Michael W, Saindane Manohar T, Andrews Meghan K, Krueger Rebecca E, Sticher Zachary M, Jung Kie Hoon, Chatterjee Payel, Shrivastava-Ranjan Punya, Lo Michael K, Coleman-McCray JoAnn D, Sorvillo Teresa E, Genzer Sarah C, Scholte Florine E M, Kelly Jamie A, Jenks M Harley, McMullan Laura K, Albariño César G, Montgomery Joel M, Painter George R, Natchus Michael G, Kolykhalov Alexander A, Gowen Brian B, Spiropoulou Christina F, Flint Mike
Аннотация
Development of broad-spectrum antiviral therapies is critical for outbreak and pandemic preparedness against emerging and reemerging viruses. Viruses inducing hemorrhagic fevers cause high morbidity and mortality in humans and are associated with several recent international outbreaks, but approved therapies for treating most of these pathogens are lacking. Here, we show that 4'-fluorouridine (4'-FlU; EIDD-2749), an orally available ribonucleoside analog, has antiviral activity against multiple hemorrhagic fever viruses in cell culture, including Nipah virus, Crimean-Congo hemorrhagic fever virus, orthohantaviruses, and arenaviruses. We performed preclinical in vivo evaluation of oral 4'-FlU against two arenaviruses, Old World Lassa virus (LASV) and New World Junín virus (JUNV), in guinea pig models of lethal disease. 4'-FlU demonstrated both advantageous pharmacokinetic characteristics and high efficacy in both of these lethal disease guinea pig models. Additional experiments supported protection of the infected animals even when 4'-FlU delivery was reduced to a low dose of 0.5 milligram per kilogram. To demonstrate clinical utility, 4'-FlU treatment was evaluated when initiated late in the course of infection (12 or 9 days after infection for LASV and JUNV, respectively). Delayed treatment resulted in rapid resolution of clinical signs, demonstrating an extended window for therapeutic intervention. These data support the use of 4'-FlU as a potent and efficacious treatment against highly pathogenic arenaviruses of public health concern with a virus inhibition profile suggesting broad-spectrum utility as an orally available antiviral drug against a wide variety of viral pathogens.